Nexalin Technology Inc (NXL)

May 28, 2025, 10:00 AM EDT - 9 days ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 13, 2025, 8:30 AM EDT - 24 days ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 6, 2025, 2:40 PM EDT - 4 weeks ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 5, 2025, 8:20 AM EDT - 4 weeks ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 1, 2025, 10:30 AM EDT - 5 weeks ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Apr 24, 2025, 9:00 AM EDT - 6 weeks ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 23, 2025, 9:15 AM EDT - 6 weeks ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 21, 2025, 8:00 AM EDT - 6 weeks ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 14, 2025, 12:30 PM EDT - 7 weeks ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 2, 2025, 8:30 AM EDT - 2 months ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Mar 26, 2025, 8:30 AM EDT - 2 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 3, 2025, 8:30 AM EST - 3 months ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Feb 28, 2025, 8:30 AM EST - 3 months ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 26, 2025, 8:30 AM EST - 3 months ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 18, 2025, 8:30 AM EST - 3 months ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 10, 2025, 9:00 AM EST - 4 months ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 3, 2025, 8:30 AM EST - 4 months ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Jan 23, 2025, 11:00 AM EST - 4 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Dec 23, 2024, 10:00 AM EST - 5 months ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nov 26, 2024, 10:00 AM EST - 6 months ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 1, 2024, 2:00 PM EDT - 7 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nov 1, 2024, 10:34 AM EDT - 7 months ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nov 1, 2024, 9:00 AM EDT - 7 months ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Oct 28, 2024, 8:30 AM EDT - 7 months ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Oct 25, 2024, 9:00 AM EDT - 8 months ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CLDI

Oct 22, 2024, 2:15 PM EDT - 8 months ago

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Oct 17, 2024, 8:30 AM EDT - 8 months ago

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Oct 14, 2024, 8:30 AM EDT - 8 months ago

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Sep 5, 2024, 9:00 AM EDT - 9 months ago

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Jul 26, 2024, 9:55 AM EDT - 11 months ago

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Jul 18, 2024, 8:30 AM EDT - 11 months ago

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Jul 1, 2024, 2:45 PM EDT - 1 year ago

Nexalin Technology Announces Closing of $5.2 Million Public Offering

Jun 27, 2024, 9:15 PM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia

Jun 14, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VNRX

Jun 13, 2024, 3:00 PM EDT - 1 year ago

Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

Jun 3, 2024, 8:30 AM EDT - 1 year ago

FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

May 22, 2024, 8:30 AM EDT - 1 year ago

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Apr 10, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology CEO Provides Letter to Shareholders

Apr 4, 2024, 1:00 PM EDT - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Mar 28, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Mar 14, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology

Mar 13, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Mar 6, 2024, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Feb 8, 2024, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Jan 23, 2024, 8:30 AM EST - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

Jan 11, 2024, 8:30 AM EST - 1 year ago

Nexalin Technology Unveils Next-Generation HALO™ Clarity

Dec 18, 2023, 8:30 AM EST - 1 year ago

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression